Dear K.T.: Dexfenfluramine, aka Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

All patients had moderate to severe symptomatic aortic regurgitation and underwent TAVR with the Trilogy valve. To date, about 360 patients have at least one year of follow-up after their ...

Out-of-hospital mortality before 30 days was 1.2%, with roughly two-thirds of these patients dying from cardiovascular causes ...

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who ... to achieve a reduction in tricuspid regurgitation to moderate or less were enrolled.

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

Boston Scientific has led a $175 million funding round for the mitral valve developer 4C ... indications in the treatment of moderate to severe mitral regurgitation and the addition of moderate ...

Cardiac Dimensions announced today that it closed an oversubscribed Series E financing round worth $53 million.

Functional mitral regurgitation is a prevalent condition among individuals with heart failure, which affects over 64 million people globally. 1 Studies indicate that moderate or greater severity ...

I saw a cardiologist and learned that I had mild to moderate mitral stenosis with regurgitation ... are still being identified now. Mitral valve disease itself may cause pulmonary hypertension ...